Cerebrospinal fluid activity of tissue plasminogen activator in patients with neurological diseases

Journal of Clinical Pathology

Volumn 49, Issue 7, 1996, Pages 577-580

  Akenami, F O T ^a,b   Siren V ^a   Koskiniemi, M ^a   Siimes, M A ^b   Teravainen H ^c   Vaheri, A ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF HELSINKI AND HELSINKI UNIVERSITY HOSPITAL   (Finland)

^c Department of Neurology ^*

Author keywords

Cerebrospinal fluid; Neurological diseases; Plasminogen activators

Indexed keywords

TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

ADOLESCENT; ADULT; AGED; ARTICLE; CEREBROSPINAL FLUID LEVEL; CHILD; CONTROLLED STUDY; ENCEPHALITIS; ENZYME ASSAY; FACIAL NERVE PARALYSIS; HUMAN; INFANT; LEUKEMIA; MAJOR CLINICAL STUDY; MENINGITIS; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; NEWBORN; PATHOGENESIS; POLYRADICULITIS; PRIORITY JOURNAL;

EID: 0030055419     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.49.7.577     Document Type: Article

References (37)

1. Danø K, Andreasen PA, Grøndahl-Hansen J, Kristensen K, Nielsen L, Skriver L. Plasminogen activators, tissue degradation and cancer. Adv Cancer Res 1985;44:139-266.
2. Pöllänen J, Stephens RW, Vaheri A. Directed plasminogen activation at the surface of normal and malignant cells. Adv Cancer Res 1991;57:273-328.
3. Aimer L-O, Sundkvist G, Lilja B. Fibrinolytic activity, autonomic neuropathy, and circulation in diabetes mellitus. Diabetes 1983;32(Suppl 2):4-7.
4. Geiger M, Binder BR. Plasminogen activation in diabetes mellitus. Kinetic analysis of plasmin formation using components isolated from the plasma of diabetic patients. J Biol Chem 1984;259:2976-81.
5. Inman RD, Harpel PC. Alpha 2-plasmin inhibitor-plasmin complexes in synovial fluid. J Rheumatol 1986;13:535-7.
6. Garcia-Frade LJ, Sureda A, Torrado MC, Garcia-Avello A. High plasma urokinase-type plasminogen activator levels are present in patients with acute nonlymphoblastic leukemia. Acta Haematol 1992;88:7-10.
7. Ridker PM, Vaughan DE, Stampfer MK, Manson JE, Hennekens CH. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet 1993; 341:1165-8.
8. Ridker PM, Hennekens CH, Stampfer MJ, Manson JE, Vaughan DE. Prospective study of endogenous tissue plasminogen activator and risk of stroke. Lancet 1994; 343:940-3.
9. Salomaa W, Wu KK, Stinson VL, Kark JD, Folsom AR, Liao D, et al. The association of fibrinolytic activity with asymptomatic carotid atherosclerosis: the ARIC study. Circulation 1993;87:22.
10. Short CD, Durrington PN, Mallick NP, Bhatnagar D, Hunt NP, Mbewu A. Serum lipoprotein (a) in men with proteinuria due to idiopathic membranous nephropathy. Nephrol Dial Transplant 1992;7(Suppl 1):109-13.
11. Bartens W, Wanner C. Lipoprotein (a): new insights into an atherogenic lipoprotein. Clin Invest 1994;72:558-67.
12. Chapman MJ, Huby T, Nigon F, Thillet J. Lipoprotein (a): implication in atherothrombosis. Atherosclerosis 1994; 110(Suppl):S69-75.
13. Gijtenbeck JM, Emeis JJ, Van der Sande JJ, Lulf RE. Different types of plasminogen activator activity in human brain tumours: relation with peritumoral oedema? Clin Neurol Neurosurg 1994;96:305-9.
14. Sawaya R, Rayford A, Kono S, Ang KK, FengY, Stephens CL, et al. Plasminogen activator inhibitor-1 in the pathogenesis of delayed radiation damage in rat spinal cord in vivo. J Neurosurg 1994;81:381-7.
15. Sutton R, Keohane ME, Van der Berg SR, Gonias SL. Plasminogen activator inhibitor-1 in the cerebrospinal fluid as an index of neurological disease. Blood Coagul Fibrinolysis 1994;5:167-71.
16. De Vries TJ, Mooy CM, Van Balken MR, Luyten GP, Quax PH, Verspaget HW, et al. Components of the plasminogen activation system in uveal melanoma a clinicopathological study. J Pathol 1995;175:59-67.
17. Carroll PM, Tsirka SE, Richards WG, Frohman MA, Strickland S. The mouse tissue plasminogen activator gene 5' flanking region directs appropriate expression in development and a seizure-enhanced response in the CNS. Development 1994;120:3173-83.
18. Garcia-Rocha M, Avila J, Armas-Porte R. Tissue-type plasminogen activators (tPA) is the main plasminogen activator associated with isolated rat nerve growth cones. Neurosci 1994;180:123-6.
19. Friedman GC, Seeds NW. Tissue plasminogen activator expression in the embryonic nervous system. Brain Res Dev Brain Res 1994;81:41-9.
20. Bizik J, Stephens RW, Grofova M, Vaheri A. Binding of tissue-type plasminogen activator to human melanoma cells. J Cell Biochem 1993;51:326-35.
21. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970;227:680-2.
22. Stephens R, Leung KC, Pöllänen J, Salonen EM, Vaheri A. Microplate immunocapture assay for plasminogen activators and their specific inhibitors. J Immunol Methods 1987; 105:245-51.
23. Stephens R, Alitalo; R, Tapiovaara H, Vaheri A. Production of an active urokinase by leukemia cells: A novel distinction from cell lines of active tumors. Leuk Res 1988; 12:419-22.
24. Deutch DG, Mertz ET. Plasminogen: Purification from human plasma by affinity chromatography. Science 1970; 170:1095-7.
25. Green GDG, Shaw E. Thiobenzyloxycarbonyl-L-lysinate, substrate for a sensitive colorimetric assay for trypsin-like enzymes. Anal Biochem 1979;93:223-6.
26. Sugita K, Suzuki N, Shimizu N, Takanashi J, Ishii M, Niimi N. Involvement of cytokines in N-methyl-N'-nitro-N-nitrosoguanidine-induced plasminogen activator activity in acute disseminated encephalomyelitis and multiple sclerosis lymphocytes. Eur Neurol 1993;33:358-62.
27. Norton WT, Brosnan CF, Cammer W, Goldmuntz EA. Mechanisms and suppression of inflammatory demyelination. Acta Neurobiol Exp (Warsz) 1990;50:225-35.
28. Dore-Duffy P, Donovan C, Todd RF 3rd. Expression of monocyte activation antigen Mo3 on the surface of peripheral blood monocytes from patients with multiple sclerosis. Neurology 1992;42:1609-14.
29. Dore-Duffy P, Washington R, Dragovic L. Expression of endothelial cell activation antigens in microvessels from patients with multiple sclerosis. Adv Exp Med Biol 1993;331:243-8.
30. Washington R, Burton J, Todd RF 3rd, Newman W, Dragovic L, Dore-Duffy P. The expression of immunologically relevant endothelial cell activation antigens on isolated central nervous system microvessels from patients with multiple sclerosis. Ann Neurol 1994;35:89-97.
31. Romanic AM, Madri JA. The extracellular matrix-degrading proteinases in the nervous system. Brain Pathol 1994;4:145-56.
32. Koskiniemi M, Vaheri A, Taskinen E. Cerebrospinal fluid alterations in herpes simplex virus encephalitis. Rev Infect Dis 1984;6:608-17.
33. Wilson EL, Jacobs P, Dowdle EB. The secretion of plasminogen activators by human myeloid leukaemic cells in vitro. Blood 1993;61:568-72.
34. Tapiovaara H, Alitalo R, Stephens R, Myöhänen H, Ruutu T, Vaheri A, Abundant urokinase activity on the surface of mononuclear cells from blood and bone marrow of acute leukemia patients. Blood 1993;82:914-19.
35. Stephens RW, Tapiovaara H, Reisberg T, Bizik J, Vaheri A. Alpha-2-macroglobulin restricts plasminogen activation to the surface of RC2A leukemia cells. Cell Regul 1991; 2:1057-65.
36. Wilson EL, Jacobs P, Francis GE, Oliver L, Burger P, Dowdle EB. Secretion of plasminogen activators by normal bone marrow cells and leukaemic myeloid cells. Fibrinolysis 1992;6(Suppl 1):77.
37. Rao JS, Chen M, Festoff BW. Plasminogen activator inhibitor 1, the primary regulator of fibrinolysis, in the normal human cerebrospinal fluid. J Neurosci Res 1993;34:340-5.